Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 41 articles: HTML format

Single Articles

April 2024
1. URYU K, Imamura Y, Shimoyama R, Mase T, et al
   Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
   Cancer Chemother Pharmacol. 2024 Apr 8. doi: 10.1007/s00280-024-04666.
   PubMed     Abstract available
   
   
   March 2024
2. HUO H, Feng Y, Tang Q
   Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
   Cancer Chemother Pharmacol. 2024 Mar 26. doi: 10.1007/s00280-024-04646.
   PubMed    
   
   
   February 2024
3. MA X, Sun Z, Chen H, Cao L, et al
   18beta-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis.
   Cancer Chemother Pharmacol. 2024 Feb 21. doi: 10.1007/s00280-024-04639.
   PubMed     Abstract available
   
   
   January 2024
4. YU F, Huo H, Tang Q
   Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
   Cancer Chemother Pharmacol. 2024 Jan 4. doi: 10.1007/s00280-023-04630.
   PubMed     Abstract available
   
   
   
5. LI MY, Zhang J, Lu X, Zhou D, et al
   Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells.
   Cancer Chemother Pharmacol. 2024;93:41-54.
   PubMed     Abstract available
   
   
   November 2023
6. WANG X, Gu S, Wen J, Zhang L, et al
   Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer.
   Cancer Chemother Pharmacol. 2023 Nov 5. doi: 10.1007/s00280-023-04608.
   PubMed     Abstract available
   
   
   
7. MA Y, Chen Q, Zhang Y, Xue J, et al
   Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
   Cancer Chemother Pharmacol. 2023;92:411-418.
   PubMed     Abstract available
   
   
   September 2023
8. CHENG M, Yang F, Yang Y, Gao X, et al
   Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer.
   Cancer Chemother Pharmacol. 2023 Sep 23. doi: 10.1007/s00280-023-04590.
   PubMed     Abstract available
   
   
   August 2023
9. NAKAHAMA K, Izumi M, Yoshimoto N, Fukui M, et al
   Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2023 Aug 22. doi: 10.1007/s00280-023-04573.
   PubMed     Abstract available
   
   
   July 2023
10. YOKOTA H, Sato K, Sakamoto S, Okuda Y, et al
    Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis.
    Cancer Chemother Pharmacol. 2023 Jul 27. doi: 10.1007/s00280-023-04569.
    PubMed     Abstract available
    
    
    
11. JACQUET E, Pham F, Taouk B, Kerouani-Lafaye G, et al
    Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab.
    Cancer Chemother Pharmacol. 2023 Jul 13. doi: 10.1007/s00280-023-04556.
    PubMed     Abstract available
    
    
    
12. KASSIR N, Chan P, Dang S, Bruno R, et al
    External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data.
    Cancer Chemother Pharmacol. 2023 Jul 6. doi: 10.1007/s00280-023-04558.
    PubMed     Abstract available
    
    
    June 2023
13. NING X, Fu Z, Zhang J, Gao S, et al
    The role of alternative splicing in lung cancer.
    Cancer Chemother Pharmacol. 2023 Jun 19. doi: 10.1007/s00280-023-04553.
    PubMed     Abstract available
    
    
    May 2023
14. HASEGAWA T, Ariyasu R, Tanaka H, Saito R, et al
    Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
    Cancer Chemother Pharmacol. 2023 May 27. doi: 10.1007/s00280-023-04547.
    PubMed     Abstract available
    
    
    January 2023
15. DE ROUW N, Boosman RJ, Burgers JA, Huitema ADR, et al
    Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.
    Cancer Chemother Pharmacol. 2023;91:33-42.
    PubMed     Abstract available
    
    
    December 2022
16. KITANO S, Fujiwara Y, Shimizu T, Iwasa S, et al
    A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
    Cancer Chemother Pharmacol. 2022;90:523-529.
    PubMed     Abstract available
    
    
    September 2022
17. XUE J, He H, Lin Z, Wu Y, et al
    Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies.
    Cancer Chemother Pharmacol. 2022;90:229-237.
    PubMed     Abstract available
    
    
    August 2022
18. AGUIAR ZDOVC J, Vaupotic M, Marolt G, Knez L, et al
    Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors.
    Cancer Chemother Pharmacol. 2022 Aug 20. pii: 10.1007/s00280-022-04465.
    PubMed     Abstract available
    
    
    July 2022
19. BARLESI F, Deyme L, Imbs DC, Cousin E, et al
    Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer.
    Cancer Chemother Pharmacol. 2022 Jul 22. pii: 10.1007/s00280-022-04455.
    PubMed     Abstract available
    
    
    
20. NAKAGAWA K, Garon EB, Gao L, Callies S, et al
    RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
    Cancer Chemother Pharmacol. 2022 Jul 16. pii: 10.1007/s00280-022-04447.
    PubMed     Abstract available
    
    
    
21. KENMOTSU H, Imamura CK, Kawamura T, Oyakawa T, et al
    Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2022 Jul 12. pii: 10.1007/s00280-022-04452.
    PubMed     Abstract available
    
    
    
22. XIONG W, Hietala SF, Nyberg J, Papasouliotis O, et al
    Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
    Cancer Chemother Pharmacol. 2022;90:53-69.
    PubMed     Abstract available
    
    
    May 2022
23. XIONG W, Papasouliotis O, Jonsson EN, Strotmann R, et al
    Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.
    Cancer Chemother Pharmacol. 2022;89:655-669.
    PubMed     Abstract available
    
    
    
24. PAPACHRISTOS A, Ratain MJ
    Lurbinectedin-induced thrombocytopenia: the role of body surface area.
    Cancer Chemother Pharmacol. 2022;89:573-575.
    PubMed     Abstract available
    
    
    April 2022
25. FELIP E, Moreno V, Morgensztern D, Curigliano G, et al
    First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
    Cancer Chemother Pharmacol. 2022;89:499-514.
    PubMed     Abstract available
    
    
    
26. BAGEGNI NA, Park H, Kraft K, O-Toole M, et al
    Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
    Cancer Chemother Pharmacol. 2022;89:487-497.
    PubMed     Abstract available
    
    
    March 2022
27. NELLI F, Virtuoso A, Berrios JRG, Giannarelli D, et al
    Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.
    Cancer Chemother Pharmacol. 2022 Mar 18. pii: 10.1007/s00280-022-04416.
    PubMed     Abstract available
    
    
    
28. MERCIER F, Djebli N, Gonzalez-Sales M, Jaminion F, et al
    Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
    Cancer Chemother Pharmacol. 2022;89:363-372.
    PubMed     Abstract available
    
    
    
29. XU F, Xi H, Liao M, Zhang Y, et al
    Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy.
    Cancer Chemother Pharmacol. 2022;89:331-346.
    PubMed     Abstract available
    
    
    January 2022
30. CHEN X, Ji R, Liu J, Jin X, et al
    Roles of DNA polymerase zeta in the radiotherapy sensitivity and oxidative stress of lung cancer cells.
    Cancer Chemother Pharmacol. 2022 Jan 23. pii: 10.1007/s00280-021-04360.
    PubMed     Abstract available
    
    
    November 2021
31. ZHANG Q, Wang W, Yuan Q, Li L, et al
    Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
    Cancer Chemother Pharmacol. 2021 Nov 25. pii: 10.1007/s00280-021-04375.
    PubMed     Abstract available
    
    
    
32. PADDA SK, Reckamp KL, Koczywas M, Neal JW, et al
    A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2021 Nov 13. pii: 10.1007/s00280-021-04369.
    PubMed     Abstract available
    
    
    
33. FERNANDEZ-TERUEL C, Fudio S, Lubomirov R
    Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
    Cancer Chemother Pharmacol. 2021 Nov 5. pii: 10.1007/s00280-021-04366.
    PubMed     Abstract available
    
    
    October 2021
34. ICHIMURA T, Hinata M, Ichikura D, Suzuki S, et al
    Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study.
    Cancer Chemother Pharmacol. 2021 Oct 14. pii: 10.1007/s00280-021-04362.
    PubMed     Abstract available
    
    
    August 2021
35. OTANI T, Yamaguchi K, Nakao S, Sakamoto S, et al
    Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
    Cancer Chemother Pharmacol. 2021 Aug 4. pii: 10.1007/s00280-021-04341.
    PubMed     Abstract available
    
    
    
36. MARCHAND M, Zhang R, Chan P, Quarmby V, et al
    Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
    Cancer Chemother Pharmacol. 2021;88:211-221.
    PubMed     Abstract available
    
    
    April 2021
37. LIU M, Yan Q, Peng B, Cai Y, et al
    Use of cucurbitacins for lung cancer research and therapy.
    Cancer Chemother Pharmacol. 2021 Apr 6. pii: 10.1007/s00280-021-04265.
    PubMed     Abstract available
    
    
    
38. VAULEON E, Behal H, Lebellec L, Desbarbieux R, et al
    Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study.
    Cancer Chemother Pharmacol. 2021;87:533-541.
    PubMed     Abstract available
    
    
    
39. HURTADO FK, de Braud F, De Castro Carpeno J, de Miguel Luken MJ, et al
    Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.
    Cancer Chemother Pharmacol. 2021;87:475-486.
    PubMed     Abstract available
    
    
    February 2021
40. CINIERO G, Elmenoufy AH, Gentile F, Weinfeld M, et al
    Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.
    Cancer Chemother Pharmacol. 2021;87:259-267.
    PubMed     Abstract available
    
    
    
41. YU S, Li Y, Ren H, Zhou H, et al
    PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.
    Cancer Chemother Pharmacol. 2021;87:207-215.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.